The status of and future research into Myalgic Encephalomyelitis and Chronic Fatigue Syndrome: the need of accurate diagnosis, objective assessment, and acknowledging biological and clinical subgroups
- ME-de-Patiënten Foundation, Limmen, Netherlands
Although Myalgic Encephalomyelitis (ME) and Chronic Fatigue Syndrome (CFS) are used interchangeably, the diagnostic criteria define two distinct clinical entities. Cognitive impairment, (muscle) weakness, circulatory disturbances, marked variability of symptoms, and, above all, post-exertional malaise: a long-lasting increase of symptoms after a minor exertion, are distinctive symptoms of ME. This latter phenomenon separates ME, a neuro-immune illness, from chronic fatigue (syndrome), other disorders and deconditioning. The introduction of the label, but more importantly the diagnostic criteria for CFS have generated much confusion, mostly because chronic fatigue is a subjective and ambiguous notion. CFS was redefined in 1994 into unexplained (persistent or relapsing) chronic fatigue, accompanied by at least four out of eight symptoms, e.g., headaches and unrefreshing sleep. Most of the research into ME and/or CFS in the last decades was based upon the multivalent CFS criteria, which define a heterogeneous patient group. Due to the fact that fatigue and other symptoms are non-discriminative, subjective experiences, research has been hampered. Various authors have questioned the physiological nature of the symptoms and qualified ME/CFS as somatization. However, various typical symptoms can be assessed objectively using standardized methods. Despite subjective and unclear criteria and measures, research has observed specific abnormalities in ME/CFS repetitively, e.g., immunological abnormalities, oxidative and nitrosative stress, neurological anomalies, circulatory deficits and mitochondrial dysfunction. However, to improve future research standards and patient care, it is crucial that patients with post-exertional malaise (ME) and patients without this odd phenomenon are acknowledged as separate clinical entities that the diagnosis of ME and CFS in research and clinical practice is based upon accurate criteria and an objective assessment of characteristic symptoms, as much as possible that well-defined clinical and biological subgroups of ME and CFS patients are investigated in more detail, and that patients are monitored before, during and after interventions with objective measures and biomarkers.
Myalgic Encephalomyelitis (ME) and Chronic Fatigue Syndrome (CFS) have been marred by much controversy (Holgate et al., 2011), from the authenticity of the symptoms (Chalder et al., 1996; Carruthers et al., 2011) and the existence of the ME and CFS as distinct clinical entities (Barsky and Borus, 1999; Twisk and Arnoldus, 2013) to the etiology (Huibers and Wessely, 2006; Carruthers et al., 2011), the pathophysiology (Vercoulen et al., 1994; Maes and Twisk, 2010) and presumed effective interventions, e.g., cognitive behavioral therapy (CBT) and graded exercise therapies (GET) (Knoop et al., 2007; Twisk and Arnoldus, 2012).
An important part of the controversy originates from the introduction of the label CFS, but even more from the definitional criteria of this clinical entity (Fukuda et al., 1994), which define a heterogeneous population of people of chronic fatigue (Wilson et al., 2001), and the use of self-reported subjective measures for ambiguous and insignificant symptoms like “fatigue” (Jason et al., 2009). The principle feature of CFS is (unexplained) chronic fatigue (Fukuda et al., 1994).
ME, whether defined by the original criteria (Ramsay, 1988) or the proposed new criteria (Carruthers et al., 2011), is not equivalent to CFS (Fukuda et al., 1994), let alone a severe form of incapacitating chronic fatigue (Sharpe et al., 1991; Reeves et al., 2005). Distinctive symptoms of ME are profound (muscle) weakness and cognitive deficits (“brain fog”). More importantly, ME can be distinguished from other diseases, chronic fatigue and deconditioning by post-exertional “malaise”: a prolonged intensification of symptoms, e.g., “brain fog” and muscle pain after a minor exertion. This distinctive phenomenon is reflected by a dramatic fall in maximum oxygen uptake and oxygen uptake and workload at the aerobic threshold at a second exercise test 24 h after the first (Snell et al., 2013) and a long-lasting increase of muscle metabolite-detecting receptors for pain and “fatigue” after moderate exercise (White et al., 2012).
Methodological issues, e.g., symptom-based criteria, the subjectivity of the symptoms, mixing patients with post-exertional “malaise” and abnormalities (ME) and patients without this phenomenon (CFS/not ME) in research and clinical practice, and assessment of the clinical status and improvement thereof in trials of proposed effective therapies using subjective measures, have yielded contradictory results and have fuelled the debate.
Despite the heterogeneity of the patient population, due to the equivocal CFS criteria, various abnormalities have been observed repetitively in the CFS patient group as a whole or in substantial subgroups of the CFS population. However, scientific progress has been slow and unnecessarily obstructed by the methodological obstacles mentioned above. In addition, due to the heterogeneity of the patients studied selected by CFS criteria, it is highly unlikely that future research will reveal one or more abnormalities that are applicable to all CFS patients.
To surmount the impasse, which has lasted for decades, it is essential to improve the standards of the research into ME/CFS, it is crucial to leave the current methods behind us and to assess symptoms objectively as much as possible, to make a clear distinction between patients with and without post-exertional abnormalities, e.g., by employing repeated cardiopulmonary exercise tests, to accurately diagnose patients using ME and CFS criteria, to define clinical and biological ME and CFS patient subgroups in research studies, and to monitor patients before, during and after trials using objective measures, however, trivial this may seem. This partly due to the fact that, in contrast with other illnesses, ME and CFS are not yet clearly defined by distinctive biomarkers. Without doing so, the debate around ME/CFS will persist.
This article summarizes the current status and is directed to the abnormalities established repeatedly and the potential improvement of diagnosis of and research into ME and CFS.
Outbreaks of a disease resembling “atypical poliomyelitis” (Gilliam, 1938) occurred from the 1940s through the 1980s at various places over the world (The Medical Staff of The Royal Free Hospital, 1957; 1978; Hyde et al., 1992). ME was identified as a new clinical entity in 1959 (Acheson, 1959) and has been acknowledged as a disease of the central nervous system/neurological disease by the World Health Organization since 1969 (WHO, 1967). The clinical picture was defined by Ramsay and co-workers (Ramsay, 1988; Dowsett et al., 1990; Jason et al., 2012a) in the 80 s. Distinctive symptoms of ME (Goodwin, 1981) are: profound (muscle) weakness and tenderness, easy fatigability of the muscles, neurological abnormalities, e.g., visual problems, cognitive deficits (concentration and memory problems), circulatory disturbances, and post-exertional “malaise”: a (delayed) long-lasting increase of symptoms after a minor physical and mental exertion.
The diagnostic entity CFS was introduced in 1988 (Holmes et al., 1988) after an outbreak in Nevada at Lake Tahoe in the mid-eighties. CFS was redefined in 1994 (Fukuda et al., 1994) into clinically evaluated, unexplained (persistent or relapsing) chronic fatigue, accompanied by at least four out of a list of eight symptoms, e.g., sore throat, unrefreshing sleep, and headaches. The majority of research into ME/CFS1 in the last two decades is based upon these case criteria. Since “fatigue” and other symptoms, e.g., unrefreshing sleep, are subjective, non-specific and ambiguous, the CFS criteria select a varied population of people with chronic fatigue (Wilson et al., 2001).
The heterogeneity of the CFS (Fukuda et al., 1994) patient population has impeded effective research and accurate diagnosis of patients. For that reason a group of researchers have proposed criteria (Carruthers et al., 2011) in order to distinguish ME from CFS (Fukuda et al., 1994) and chronic fatigue (Sharpe et al., 1991). According to this new criteria post-exertional “malaise” or “neuro-immune exhaustion” (“a pathological inability to produce sufficient energy on demand” resulting into symptom exacerbation, e.g., flu-like symptoms and pain, after minor exertion) is obligatory for the diagnosis ME. Post-exertional “malaise” should be accompanied by specific neurological symptoms, impaired cellular energy metabolism and/or transportation, and immune, gastro-intestinal or genitourinary symptoms.
ME vs. CFS
Although ME and CFS are considered to be interchangeable labels (WHO, 1992), criteria for ME (Carruthers et al., 2011) and CFS (Fukuda et al., 1994) define distinct, partially overlapping clinical entities (Twisk and Arnoldus, 2013). Post-exertional malaise and cognitive deficits e.g., are not mandatory for the diagnosis CFS, while these symptoms are obligatory for the diagnosis ME. “Fatigue” is not obligatory to meet the diagnosis ME. The distinction between patients with ME/CFS with post-exertional malaise and patients without post-exertional malaise is reflected by particular clinical and immunological differences (Maes et al., 2012a; Brenu et al., 2013).
Prevalence and Impact
Nacul et al. (2011) found that 0.19% of 143,000 individuals (18–64 years) met the commonly used Fukuda criteria for CFS (Fukuda et al., 1994), while 0.11% met the more strict criteria for ME/CFS (Carruthers et al., 2003), including post-exertional malaise. Prevalence rates of ME (Carruthers et al., 2011) remain to be investigated, but based upon (Nacul et al., 2011; Jason et al., 2012b; Maes et al., 2012a; Brenu et al., 2013) it is estimated that 30–50% of the subjects meeting the CFS (Fukuda et al., 1994) criteria fulfill the more stringent criteria for ME (Carruthers et al., 2011). Patients experience significantly more impairment than patients with hypertension, congestive heart failure, type II diabetes mellitus, acute myocardial infarction, multiple sclerosis and depression (Komaroff et al., 1996). The ME/CFS criteria (Carruthers et al., 2003) select patients with more disability and more physical, mental and cognitive symptoms than patients with the diagnosis CFS (Fukuda et al., 1994) not meeting these criteria (Jason et al., 2012b).
Nowadays, the diagnoses ME and CFS are often based upon subjective measures reported by patients, e.g., fatigue (Chalder et al., 1993; Vercoulen et al., 1994) and physical functioning (Ware and Sherbourne, 1992; McHorney et al., 1993). However, to bypass problems created by ambiguous symptom-based criteria, e.g., heterogeneity of the patient population, a clinical assessment ME of CFS and its severity should be based upon objective measures as much as possible. Several distinctive symptoms can be assessed objectively (see Table 1).
Symptoms that cannot be assessed objectively easily due to their nature, are: “fatigue”, widespread muscle and/or joint pain, often amplified after a (minor) exertion, hypersensitivity to light, sound, odor and chemicals, e.g., anaesthetics (likely due to “central sensitization”), thermoregulation problems and “sickness behavior.” Research (Jason et al., 2014) has shown that minimum frequency and severity thresholds should be used for self-reported symptoms to reduce the likelihood of misclassification.
The heterogeneity of the patient population (Whistler et al., 2003) and the use of various methods and samples have contributed to conflicting results. Despite this various specific abnormalities have been observed repetitively in the ME/CFS patient population or substantial subgroup thereof (Table 2).
Various of the abnormalities mentioned in Table 2 are reflected by deviant gene expression (Kaushik et al., 2005; Whistler et al., 2005; Fuite et al., 2008; Gow et al., 2009). Aberrations at the cellular level include mitochondrial dysfunction (Booth et al., 2012), inflammation, immunosuppression, e.g., reduced Natural Killer cell lytic activity (Hardcastle et al., 2014), immune dysfunction, e.g., increased synthesis of (Th2-associated) cytokines (Fletcher et al., 2009), increased production of inducible nitric oxide (NO) synthase by peripheral lymphocytes (Maes et al., 2007b). Tissue anomalies encompass significantly low oxygen uptake by muscle cells (Vermeulen and Vermeulen van Eck, 2014), increased intramuscular acidosis after maximal voluntary contraction with significantly prolonged pH recovery times (Jones et al., 2012), an inverse correlation between increased skeletal muscle pH and reduced cerebral blood flow at rest and during dynamic stimulation (He et al., 2013), and differential expression of genes with key roles in mitochondrial function and oxidative balance in the vastus lateralis muscle (Pietrangelo et al., 2009). Neurological abnormalities in ME/CFS patients or subgroups thereof include reduced gray and white brain matter (Puri et al., 2012), increased magnetic resonance imaging (MRI) abnormalities, mainly T2 signal hyperintensities in the frontal lobes (Lange et al., 1999), significant reductions in cerebral blood flow across various brain regions (Yoshiuchi et al., 2006), spinal fluid abnormalities (Natelson et al., 2005) and increased ventricular lactate (Shungu et al., 2012).
Since many of the research studies which observed aberrations in ME/CFS compared patients with sedentary controls, the abnormalities cannot be attributed to deconditioning. Whether the name ME is appropriate or not remains subject of debate (Van der Meer and Lloyd, 2012), but various findings in ME/CFS actually indicate muscular and neurological abnormalities. However, immunological abnormalities, antigens, increased oxidative and nitrosative stress, and gastro-intestinal dysfunction seem to be at the core of the etiology of ME/CFS (Maes and Twisk, 2010). The distinction between patients meeting the proposed criteria for ME (Carruthers et al., 2011) and patients with CFS (Fukuda et al., 1994) not fulfilling these criteria is reflected by specific immunological abnormalities (Brenu et al., 2013).
Exercise and orthostatic stress seems to induce or intensify (long lasting) abnormalities in patient subgroups, e.g., a significant decrease of the oxygen consumption and workload at exhaustion and at the ventilatory (anaerobic) threshold at a second exercise test 24 h later (Snell et al., 2013); a long-term increase of messenger RNA (mRNA) of metabolite-detecting receptors after sustained moderate exercise (White et al., 2012); a significant prolongation of the time taken for pH to recover to baseline after exercise (Jones et al., 2012); reduced prefrontal oxygenation during exercise and recovery when compared to healthy controls similar in physical activity levels (Patrick Neary et al., 2008); impaired cognitive functioning 24 h after physically demanding exercise compared with sedentary healthy individuals (LaManca et al., 1998); and an substantially higher increase in NO metabolites in relation to workload during exercise (Suárez et al., 2010).
Although the exact etiological mechanisms remains to be elucidated, the post-exertional malaise phenomenon could arguably be explained by the observation that physical stress, particularly anaerobic exercise, can intensify pre-existing abnormalities: inflammation (Fisher-Wellman and Bloomer, 2009; Mogharnas et al., 2011; Sakharov et al., 2012), immunosuppression (Millard et al., 2013), immune dysfunction (Steensberg et al., 2001), oxidative and nitrosative stress (Bloomer et al., 2005; Fisher-Wellman and Bloomer, 2009; Sakharov et al., 2012) and hyperpermeability of the intestines (Lambert, 2009; Lamprecht and Frauwallner, 2012). Since the anaerobic threshold is already low in ME/CFS patients or subgroups (De Becker et al., 2000; Vermeulen et al., 2010), the effects of exercise programmes should be monitored objectively and continuously, e.g., by using CPET.
In addition to a breakdown into patients with post-exertional malaise (ME) and without this hallmark feature (CFS/not ME), a subdivision into subgroups based upon onset (sudden/viral? or gradual), type and severity of symptoms, gender, age, duration and/or comorbidities seems inevitable to unravel common and distinct deviant biological pathways in more detail. Potentially relevant clinical subdivisions are summarized in Table S1 (see Supplementary Material).
Several studies have revealed distinct biological ME/CFS patient subgroups, often associated with distinct differences in the clinical picture as illustrated in Table S2 (Supplementary Material). The most relevant subdivisions are based upon (exercise-induced) immunological abnormalities. Acknowledging immunological, infectious and endocrine subdivisions seem to be crucial to establish the efficacy and safety of pharmacological and behavioral therapies. In addition to differential gene expression genes in all patients, upregulation and downregulation of specific genes are likely to reflect specific (biological and clinical) ME/CFS patient subgroups.
Although ME and CFS are considered to be equivalents (WHO, 1992), the diagnostic criteria for ME (Ramsay, 1988; Dowsett et al., 1990; Carruthers et al., 2011; Jason et al., 2012a) and CFS (Sharpe et al., 1991; Fukuda et al., 1994; Reeves et al., 2005) define distinct clinical, partly overlapping, entities. CFS criteria focus primarily on chronic fatigue, which, due to is nature, is a subjective and ambiguous criterion (Jason et al., 2010, 2011a; Davenport et al., 2011). ME is principally characterized by neurocognitive impairment, (muscle) weakness and sleep disturbances, but the distinctive feature of ME is post-exertional “malaise”: a (long-lasting) aggravation of symptoms, e.g., pain, “brain fog” and weakness, after a minor physical or mental exertion (Carruthers et al., 2011; Maes et al., 2012a).
The question whether the label ME is appropriate (Baraniuk et al., 2005; Schutzer et al., 2011) or not remains to be established, but considering the confusion due to the introduction of chronic fatigue as the principle criterion and the use of symptom-based criteria and questionnaires in clinical practice and research, it seems crucial to assess various characteristic symptoms objectively and to make a clear distinction between patients with post-exertional malaise (ME) and patients without post-exertional malaise. Objective tests, e.g., repeated exercise tests (CPETs) and tilt table testing, could be employed as a solid basis for the diagnosis, the validation, adjustment and refinement of ME (Carruthers et al., 2011) and CFS (Fukuda et al., 1994) criteria and the definition of clinical ME and CFS patients subgroups in research.
Trials into the efficacy and safety of pharmacological (Fluge et al., 2011; Watt et al., 2012) and behavioral therapies, e.g., CBT and GET (Knoop et al., 2007; Heins et al., 2010; White et al., 2011), should employ objective measures of the clinical status and improvement thereof and biomarkers to establish the effects of these therapies in specific clinical and biological subgroups (Kindlon, 2012). To unravel the enigma and to resolve the controversy, patients should be monitored before, during and after potentially effective therapies in research and clinical practice using objective measures (Kindlon, 2012), e.g., oxygen uptake at the anaerobic threshold and maximum oxygen uptake (VO2max), and biomarkers, e.g., (exercise-induced) cytokine levels.
Looking at the definitional criteria of ME, e.g., (muscle) weakness, cognitive impairment, but above all post-exertional “malaise,” ME is not equivalent to CFS, let alone chronic fatigue. The introduction of the label CFS, but more importantly a fatigue-based case definition, have resulted into research of a heterogeneous patient population of patients with chronic fatigue. Combined with the use of subjective measures this has created confusion and controversy.
Several authors have questioned the validity and nature of symptoms reported by patients. This debate can be resolved by assessing characteristic symptoms using objective methods, if possible, e.g., repeated exercise tests, cognitive tests, orthostatic testing and visual tests.
Despite the ambiguous CFS criteria and methods applied, researchers have observed various specific abnormalities repeatedly, e.g., (reactivating or chronic) infections, immunological anomalies (inflammation, immune activation and dysfunction), and long lasting deviant effects of exercise, in the ME/CFS patient population or substantial subgroups thereof.
However, in order to advance in research and clinical practice, to unravel the enigmatic cause(s) of ME and CFS and to develop effective therapies, it seems crucial (a) that patients with post-exertional “malaise” (ME) and “CFS” patients without post-exertional phenomena are acknowledged as two separate clinical and research entities; (b) that typical symptoms of ME and CFS are assessed objectively as much as possible; (c) that well-defined clinical subgroups of ME and CFS, e.g., patients with orthostatic intolerance or patients with sudden-onset, are investigated in more detail; (d) that biomarkers, e.g., immunological status in rest and after exertion, are used to distinguish biological subtypes in research; and (e) that trials into the efficacy of therapies use objective measures of the clinical status and biomarkers to establish the effects of these therapies in ME or CFS patients or subgroups thereof impartially, e.g., by a (positive) change in the oxygen uptake at the anaerobic threshold and cognitive tests scores.
Considering the central role of post-exertional and cognitive impairment (“brain fog”) in ME/CFS, interesting areas of research include exercise-induced abnormalities, e.g., immune responses, oxidative and nitrosative stress, oxygen uptake, mitochondrial dysfunction, and brain energetics before, during and after exercise and cognitive stimulation (Quistorff et al., 2008; Bergersen and Gjedde, 2012; Shungu et al., 2012).
Conflict of Interest Statement
The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
The Supplementary Material for this article can be found online at: http://www.frontiersin.org/journal/10.3389/fphys.2014.00109/abstract
- ^ME/CFS refers to ME and/or CFS.
Aschbacher, K., Adam, E. K., Crofford, L. J., Kemeny, M. E., Demitrack, M. A., and Ben-Zvi, A. (2012). Linking disease symptoms and subtypes with personalized systems-based phenotypes: a proof of concept study. Brain Behav. Immun. 26, 1047–1056. doi: 10.1016/j.bbi.2012.06.002
American College of Cardiology, Benditt, D. G., Ferguson, D. W., Grubb, B. P., Kapoor, W. N., Kugler, J., et al. (1996). Tilt table testing for assessing syncope. J. Am. Coll. Cardiol. 28, 263–275. doi: 10.1016/0735-1097(96)00236-7
Acheson, E. D. (1959). The clinical syndrome variously called benign myalgic encephalomyelitis, Iceland disease and epidemic neuromyasthenia. Am. J. Med. 26, 569–595. doi: 10.1016/0002-9343(59)90280-3
Amann, M., Subudhi, A. W., Walker, J., Eisenman, P., Shultz, B., and Foster, C. (2004). An evaluation of the predictive validity and reliability of ventilatory threshold. Med. Sci. Sports Exerc. 36, 1716–1722. doi: 10.1249/01.MSS.0000142305.18543.34
Badham, S. P., and Hutchinson, C. V. (2013). Characterising eye movement dysfunction in myalgic encephalomyelitis/chronic fatigue syndrome. Graefes Arch. Clin. Exp. Ophthalmol. 251, 2769–2776. doi: 10.1007/s00417-013-2431-3
Balady, G. J., Arena, R., Sietsema, K., Myers, J., Coke, L., Fletcher, G. F., et al. (2010). Clinician's Guide to cardiopulmonary exercise testing in adults: a scientific statement from the American Heart Association. Circulation 122, 191–225. doi: 10.1161/CIR.0b013e3181e52e69
Ball, K., Owsley, C., Sloane, M. E., Roenker, D. L., and Bruni, J. R. (1993). Visual attention problems as a predictor of vehicle crashes in older drivers. Invest. Ophthalmol. Vis. Sci. 34, 3110–3123.
Baraniuk, J. N., Casado, B., Maibach, H., Clauw, D. J., Pannell, L. K., and Hess, S. S. (2005). A chronic fatigue syndrome - related proteome in human cerebrospinal fluid. BMC Neurol. 5:22. doi: 10.1186/1471-2377-5-22
Bensimhon, D. R., Leifer, E. S., Ellis, S. J., Fleg, J. L., Keteyian, S. J., Piña, I. L., et al. (2008). Reproducibility of peak oxygen uptake and other cardiopulmonary exercise testing parameters in patients with heart failure (from the Heart Failure and A Controlled Trial Investigating Outcomes of exercise traiNing). Am. J. Cardiol. 102, 712–717. doi: 10.1016/j.amjcard.2008.04.047
Biswal, B., Kunwar, P., and Natelson, B. H. (2011). Cerebral blood flow is reduced in chronic fatigue syndrome as assessed by arterial spin labeling. J. Neurol. Sci. 301, 9–11. doi: 10.1016/j.jns.2010.11.018
Bloomer, R. J., Goldfarb, A. H., Wideman, L., McKenzie, M. J., and Consitt, L. A. (2005). Effects of acute aerobic and anaerobic exercise on blood markers of oxidative stress. J. Strength Cond. Res. 19, 276–285. doi: 10.1519/14823.1
Booth, N. E., Myhill, S., and McLaren-Howard, J. (2012). Mitochondrial dysfunction and the pathophysiology of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). Int. J. Clin. Exp. Med. 5, 208–220.
Brenu, E. W., Johnston, S., Hardcastle, S. L., Huth, T. K., Fuller, K., Ramos, S. B., et al. (2013). Immune abnormalities in patients meeting new diagnostic criteria for chronic fatigue syndrome/Myalgic Encephalomyelitis. J. Mol. Biomark. Diagn. 4, 152. doi: 10.4172/2155-9929.1000152
Brenu, E. W., van Driel, M. L., Staines, D. R., Ashton, K. J., Ramos, S. B., Keane, J., et al. (2011). Immunological abnormalities as potential biomarkers in chronic fatigue syndrome/myalgic encephalomyelitis. J. Transl. Med. 9, 81. doi: 10.1186/1479-5876-9-81
Broderick, G., Craddock, R. C., Whistler, T., Taylor, R., Klimas, N., and Unger, E. R. (2006). Identifying illness parameters in fatiguing syndromes using classical projection methods. Pharmacogenomics 7, 407–419. doi: 10.2217/146224188.8.131.527
Broderick, G., Fuite, J., Kreitz, A., Vernon, S. D., Klimas, N., and Fletcher, M. A. (2010). A formal analysis of cytokine networks in chronic fatigue syndrome. Brain Behav. Immun. 24, 1209–1217. doi: 10.1016/j.bbi.2010.04.012
Cameron, B., Galbraith, S., Zhang, Y., Davenport, T., Vollmer-Conna, U., Wakefield, D., et al. (2007). Gene expression correlates of postinfective fatigue syndrome after infectious mononucleosis. J. Infect. Dis. 196, 56–66. doi: 10.1086/518614
Carruthers, B. M., Jain, A. K., de Meirleir, K. L., Peterson, D. L., Klimas, N. G., Lerner, A. M., et al. (2003). Myalgic encephalomyelitis/chronic fatigue syndrome - clinical working case definition, diagnostic and treatment protocols. J. Chronic Fatigue Syndr. 11, 7–115. doi: 10.1300/J092v11n01_02
Carruthers, B. M., van de Sande, M. I., de Meirleir, K. L., Klimas, N. G., Broderick, G., Mitchell, T., et al. (2011). Myalgic Encephalomyelitis: international consensus criteria. J. Intern. Med. 270, 327–338. doi: 10.1111/j.1365-2796.2011.02428.x
Chapenko, S., Krumina, A., Logina, I., Rasa, S., Chistjakovs, M., Sultanova, A., et al. (2012). Association of active human herpesvirus-6, -7 and parvovirus B19 infection with clinical outcomes in patients with myalgic encephalomyelitis/chronic fatigue syndrome. Adv. Virol. 2012:205085. doi: 10.1155/2012/205085
Chen, R., Liang, F. X., Moriya, J., Yamakawa, J., Sumino, H., Kanda, T., et al. (2008). Chronic fatigue syndrome and the central nervous system. J. Int. Med. Res. 36, 867–874. doi: 10.1177/147323000803600501
Chia, J., Chia, A., Voeller, M., Lee, T., and Chang, R. (2010). Acute enterovirus infection followed by myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and viral persistence. J. Clin. Pathol. 63, 165–168. doi: 10.1136/jcp.2009.070466
Clark, M. R., Katon, W., Russo, J., Kith, P., Sintay, M., and Buchwald, D. (1995). Chronic fatigue: risk factors for symptom persistence in a 2 1/2-year follow-up study. Am. J. Med. 98, 187–195. doi: 10.1016/S0002-9343(99)80403-3
Claypoole, K. H., Noonan, C., Mahurin, R. K., Goldberg, J., Erickson, T., and Buchwald, D. (2007). A twin study of cognitive function in chronic fatigue syndrome: the effects of sudden illness onset. Neuropsychology 21, 507–513. doi: 10.1037/0894-4184.108.40.2067
Constant, E. L., Adam, S., Gillain, B., Lambert, M., Masquelier, E., and Seron, X. (2011). Cognitive deficits in patients with chronic fatigue syndrome compared to those with major depressive disorder and healthy controls. Clin. Neurol. Neurosurg. 113, 295–302. doi: 10.1016/j.clineuro.2010.12.002
Cook, D. B., Lange, G., DeLuca, J., and Natelson, B. H. (2001). Relationship of brain MRI abnormalities and physical functional status in chronic fatigue syndrome. Int. J. Neurosci. 107, 1–6. doi: 10.3109/00207450109149754
Cook, D. B., Nagelkirk, P. R., Peckerman, A., Poluri, A., Mores, J., and Natelson, B. H. (2005). Exercise and cognitive performance in chronic fatigue syndrome. Med. Sci. Sports Exerc. 37, 1460–1467. doi: 10.1249/01.mss.0000179921.48404.ef
Davenport, T. E., Stevens, S. R., Baroni, K., M, V. N., and Snell, C. R. (2011). Diagnostic accuracy of symptoms characterising chronic fatigue syndrome. Disabil. Rehabil. 33, 1768–1775. doi: 10.3109/09638288.2010.546936
De Becker, P., Roeykens, J., Reynders, M., McGregor, N., and de Meirleir, K. (2000). Exercise capacity in chronic fatigue syndrome. Arch. Intern. Med. 160, 3270–3277. doi: 10.1001/archinte.160.21.3270
De Lorenzo, F., Hargreaves, J., and Kakkar, V. V. (1997). Pathogenesis and management of delayed orthostatic hypotension in patients with chronic fatigue syndrome. Clin. Auton. Res. 7, 185–190. doi: 10.1007/BF02267980
DeLuca, J., Christodoulou, C., Diamond, B. J., Rosenstein, E. D., Kramer, N., and Natelson, B. H. (2004). Working memory deficits in chronic fatigue syndrome: differentiating between speed and accuracy of information processing. J. Int. Neuropsychol. Soc. 10, 101–109. doi: 10.1017/S1355617704101124
DeLuca, J., Johnson, S. K., Ellis, S. P., and Natelson, B. H. (1997a). Sudden vs gradual onset of chronic fatigue syndrome differentiates individuals on cognitive and psychiatric measures. J. Psychiatr. Res. 31, 83–90. doi: 10.1016/S0022-3956(96)00052-0
DeLuca, J., Johnson, S. K., Ellis, S. P., and Natelson, B. H. (1997b). Cognitive functioning is impaired in patients with chronic fatigue syndrome devoid of psychiatric disease. J. Neurol. Neurosurg. Psychiatr. 62, 151–155. doi: 10.1136/jnnp.62.2.151
De Meirleir, K. L., Khaiboullina, S. F., Frémont, M., Hulstaert, J., Rizvanov, A. A., Palotás, A., et al. (2013). Plasmacytoid dendritic cells in the duodenum of individuals diagnosed with myalgic encephalomyelitis are uniquely immunoreactive to antibodies to human endogenous retroviral proteins. In Vivo 27, 177–187.
Demitrack, M. A., Dale, J. K., Straus, S. E., Laue, L., Listwak, S. J., Kruesi, M. J., et al. (1991). Evidence for impaired activation of the hypothalamic-pituitary-adrenal axis in patients with chronic fatigue syndrome. J. Clin. Endocrinol. Metab. 73, 1224–1234. doi: 10.1210/jcem-73-6-1224
Dickson, A., Toft, A., and O'Carroll, R. E. (2009). Neuropsychological functioning, illness perception, mood and quality of life in chronic fatigue syndrome, autoimmune thyroid disease and healthy participants. Psychol. Med. 39, 1567–1576. doi: 10.1017/S0033291708004960
Dumermuth, G., Lange, B., Lehmann, D., Meier, C. A., Dinkelmann, R., and Molinari, L. (1983). Spectral analysis of all-night sleep EEG in healthy adults. Eur. Neurol. 22, 322–339. doi: 10.1159/000115579
Farquhar, W. B., Hunt, B. E., Taylor, J. A., Darling, S. E., and Freeman, R. (2002). Blood volume and its relation to peak O(2) consumption and physical activity in patients with chronic fatigue. Am. J. Physiol. Heart Circ. Physiol. 282, H66–H71.
Fluge, Ø., Bruland, O., Risa, K., Storstein, A., Kristoffersen, E. K., Sapkota, D., et al. (2011). Benefit from B-lymphocyte depletion using the anti-CD20 antibody rituximab in chronic fatigue syndrome. A double-blind and placebo-controlled study. PLoS ONE 6:e26358. doi: 10.1371/journal.pone.0026358
Frémont, M., Coomans, D., Massart, S., and de Meirleir, K. (2013). High-throughput 16S rRNA gene sequencing reveals alterations of intestinal microbiota in myalgic encephalomyelitis/chronic fatigue syndrome patients. Anaerobe 22, 50–56. doi: 10.1016/j.anaerobe.2013.06.002
Friedberg, F., Dechene, L., and McKenzie, M. J. 2nd, Fontanetta, R. (2000). Symptom patterns in long-duration chronic fatigue syndrome. J. Psychosom. Res. 48, 59–68. doi: 10.1016/S0022-3999(99)00077-X
Fuite, J., Vernon, S. D., and Broderick, G. (2008). Neuroendocrine and immune network re-modeling in chronic fatigue syndrome: an exploratory analysis. Genomics 92, 393–399. doi: 10.1016/j.ygeno.2008.08.008
Fukuda, K., Straus, S. E., Hickie, I., Sharpe, M., Dobbins, J. G., and Komaroff, A. L. (1994). The chronic fatigue syndrome: a comprehensive approach to its definition and study. Ann. Intern. Med. 121, 953–959. doi: 10.7326/0003-4819-121-12-199412150-00009
Fulcher, K. Y., and White, P. D. (2000). Strength and physiological response to exercise in patients with chronic fatigue syndrome. J. Neurol. Neurosurg. Psychiatr. 69, 302–307. doi: 10.1136/jnnp.69.3.302
Gaab, J., Engert, V., Heitz, V., Schad, T., Schürmeyer, T. H., and Ehlert, U. (2004). Associations between neuroendocrine responses to the insulin tolerance test and patient characteristics in chronic fatigue syndrome. J. Psychosom. Res. 56, 419–424. doi: 10.1016/S0022-3999(03)00625-1
Gaab, J., Hüster, D., Peisen, R., Engert, V., Heitz, V., Schad, T., et al. (2002). Hypothalamic-pituitary-adrenal axis reactivity in chronic fatigue syndrome and health under psychological, physiological, and pharmacological stimulation. Psychosom. Med. 64, 951–962. doi: 10.1097/01.PSY.0000038937.67401.61
Galland, B. C., Jackson, P. M., Sayers, R. M., and Taylor, B. J. (2008). A matched case control study of orthostatic intolerance in children/adolescents with chronic fatigue syndrome. Pediatr. Res. 63, 196–202. doi: 10.1203/PDR.0b013e31815ed612
Gilliam, A. G. (1938). Epidemiological Study on an Epidemic, Diagnosed as Poliomyelitis, Occurring Among the Personnel of Los Angeles County General Hospital During the Summer of 1934. Public Health Bulletin: 240. Washington, DC: National Institutes of Health (US).
Gow, J. W., Hagan, S., Herzyk, P., Cannon, C., Behan, P. O., and Chaudhuri, A. (2009). A gene signature for post-infectious chronic fatigue syndrome. BMC Med. Genomics 2:38. doi: 10.1186/1755-8794-2-38
Groeger, D., O'Mahony, L., Murphy, E. F., Bourke, J. F., Dinan, T. G., Kiely, B., et al. (2013). Bifidobacterium infantis 35624 modulates host inflammatory processes beyond the gut. Gut Microbes 4, 325–339. doi: 10.4161/gmic.25487
Hardcastle, S. L., Brenu, E. W., Johnston, S., Nguyen, T., Huth, T., Kaur, M., et al. (2014). Analysis of the relationship between immune dysfunction and symptom severity in patients with Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME). J. Clin. Cell. Immunol. 5, 190. doi: 10.4172/2155-9899.1000190
He, J., Hollingsworth, K. G., Newton, J. L., and Blamire, A. M. (2013). Cerebral vascular control is associated with skeletal muscle pH in chronic fatigue syndrome patients both at rest and during dynamic stimulation. Neuroimage Clin. 2, 168–173. doi: 10.1016/j.nicl.2012.12.006
Heins, M. J., Knoop, H., Prins, J. B., Stulemeijer, M., van der Meer, J. W. M., and Bleijenberg, G. (2010). Possible detrimental effects of cognitive behaviour therapy for chronic fatigue syndrome. Psychother. Psychosom. 79, 249–256. doi: 10.1159/000315130
Hoad, A., Spickett, G., Elliott, J., and Newton, J. (2008). Postural orthostatic tachycardia syndrome is an under-recognized condition in chronic fatigue syndrome. QJM 101, 961–965. doi: 10.1093/qjmed/hcn123
Hollingsworth, K. G., Hodgson, T., Macgowan, G. A., Blamire, A. M., and Newton, J. L. (2012). Impaired cardiac function in chronic fatigue syndrome measured using magnetic resonance cardiac tagging. J. Intern. Med. 271, 264–270. doi: 10.1111/j.1365-2796.2011.02429.x
Holtorf, K. (2008). Diagnosis and treatment of hypothalamic-pituitary-adrenal (HPA) axis dysfunction in patients with chronic fatigue syndrome (CFS) and fibromyalgia (FM). J. Chronic Fatigue Syndr. 14, 59–88. doi: 10.1300/J092v14n03_06
Hurwitz, B. E., Coryell, V. T., Parker, M., Martin, P., Laperriere, A., Klimas, N. G., et al. (2009). Chronic fatigue syndrome: illness severity, sedentary lifestyle, blood volume and evidence of diminished cardiac function. Clin. Sci. 118, 125–135. doi: 10.1042/CS20090055
Iber, C., Ancoli-Israel, S., Chesson, A., and Quan, S. F. (2007). The AASM Manual for the Scoring of Sleep and Associated Events: Rules, Terminology, and Technical Specifications. 1st Edn. Westchester, IL: American Academy of Sleep Medicine.
Jammes, Y., Steinberg, J. G., and Delliaux, S. (2012). Chronic fatigue syndrome: acute infection and history of physical activity affect resting levels and response to exercise of plasma oxidant/antioxidant status and heat shock proteins. J. Intern. Med. 272, 74–84. doi: 10.1111/j.1365-2796.2011.02488.x
Jammes, Y., Steinberg, J. G., Delliaux, S., and Brégeon, F. (2009). Chronic fatigue syndrome combines increased exercise-induced oxidative stress and reduced cytokine and Hsp responses. J. Intern. Med. 266, 196–206. doi: 10.1111/j.1365-2796.2009.02079.x
Jason, L. A., Brown, A., Clyne, E., Bartgis, L., Evans, M., and Brown, M. (2012b). Contrasting case definitions for chronic fatigue syndrome, myalgic encephalomyelitis/chronic fatigue syndrome and myalgic encephalomyelitis. Eval. Health Prof. 35, 280–304. doi: 10.1177/0163278711424281
Jason, L. A., Damrongvachiraphan, D., Hunnell, J., Bartgis, L., Brown, A., Evans, M., et al. (2012a). Myalgic encephalomyelitis case definitions. Automatic Control Physiol. State Funct. 1:K110601. doi: 10.4303/acpsf/K110601
Jason, L. A., Evans, M., Brown, A., Brown, M., Porter, N., Hunnell, J., et al. (2010). Sensitivity and specificity of the CDC empirical chronic fatigue syndrome case definition. Psychology 1, 9–16. doi: 10.4236/psych.2010.11002
Jason, L. A., Evans, M., Brown, M., Porter, N., Brown, A., Hunnell, J., et al. (2011a). Fatigue scales and chronic fatigue syndrome: issues of sensitivity and specificity. Disabil. Stud. Q. 31, pii: 1375.
Jason, L. A., Jessen, T., Porter, N., Boulton, A., Gloria-Njoku, M., and Friedberg, F. (2009). Examining types of fatigue among individuals with ME/CFS. Disabil. Stud. Q. 29. Available online at: http://www.dsq-sds.org/article/view/938/1113.
Jason, L. A., Sunnquist, M., Brown, A., Evans, M., Vernon, S. D., Furst, J. D., et al. (2014). Examining case definition criteria for chronic fatigue syndrome and myalgic encephalomyelitis. Fatigue. Biomed. Health Behav. 2, 40–56. doi: 10.1080/21641846.2013.862993
Jerjes, W. K., Cleare, A. J., Wessely, S., Wood, P. J., and Taylor, N. F. (2005). Diurnal patterns of salivary cortisol and cortisone output in chronic fatigue syndrome. J. Affect. Disord. 87, 299–304. doi: 10.1016/j.jad.2005.03.013
Jones, D. E., Hollingsworth, K. G., Jakovljevic, D. G., Fattakhova, G., Pairman, J., Blamire, A. M., et al. (2012). Loss of capacity to recover from acidosis on repeat exercise in chronic fatigue syndrome: a case-control study. Eur. J. Clin. Invest. 42, 186–194. doi: 10.1111/j.1365-2362.2011.02567.x
Katz, B. Z., Stewart, J. M., Shiraishi, Y., Mears, C. J., and Taylor, R. (2011). Autonomic symptoms at baseline and following infectious mononucleosis in a prospective cohort of adolescents. Arch. Pediatr. Adolesc. Med. 165, 765–766. doi: 10.1001/archpediatrics.2011.124
Kaushik, N., Fear, D., Richards, S. C., McDermott, C. R., Nuwaysir, E. F., Kellam, P., et al. (2005). Gene expression in peripheral blood mononuclear cells from patients with chronic fatigue syndrome. J. Clin. Pathol. 58, 826–832. doi: 10.1136/jcp.2005.025718
Kennedy, G., Khan, F., Hill, A., Underwood, C., and Belch, J. F. (2010). Biochemical and vascular aspects of pediatric chronic fatigue syndrome. Arch. Pediatr. Adolesc. Med. 164, 817–823. doi: 10.1001/archpediatrics.2010.157
Kerr, J. R., Petty, R., Burke, B., Gough, J., Fear, D., Sinclair, L. I., et al. (2008a). Gene expression subtypes in patients with chronic fatigue syndrome/myalgic encephalomyelitis. J. Infect. Dis. 197, 1171–1184. doi: 10.1086/533453
Kerr, J. R., Burke, B., Petty, R., Gough, J., Fear, D., Mattey, D. L., et al. (2008b). Seven genomic subtypes of chronic fatigue syndrome/myalgic encephalomyelitis: a detailed analysis of gene networks and clinical phenotypes. J. Clin. Pathol. 61, 730–739. doi: 10.1136/jcp.2007.053553
Kindlon, T. (2012). Objective compliance and outcome measures should be used in trials of exercise interventions for chronic fatigue syndrome. Eur. J. Clin. Invest. 42, 1360–1361. doi: 10.1111/j.1365-2362.2012.02724.x
Kirschbaum, C., Pirke, K. M., and Hellhammer, D. H. (1993). The ‘Trier social stress test’ - a tool for investigating psychobiological stress responses in a laboratory setting. Neuropsychobiology 28, 76–81. doi: 10.1159/000119004
Kishi, A., Natelson, B. H., Togo, F., Struzik, Z. R., Rapoport, D. M., and Yamamoto, Y. (2011). Sleep-stage dynamics in patients with chronic fatigue syndrome with or without fibromyalgia. Sleep 34, 1551–1560. doi: 10.5665/sleep.1396
Kishi, A., Struzik, Z. R., Natelson, B. H., Togo, F., and Yamamoto, Y. (2008). Dynamics of sleep stage transitions in healthy humans and patients with chronic fatigue syndrome. Am. J. Physiol. Regul. Integr. Comp. Physiol. 294, R1980–R1987. doi: 10.1152/ajpregu.00925.2007
Knoop, H., Bleijenberg, G., Gielissen, M. F., van der Meer, J. W. M., and White, P. D. (2007). Is a full recovery possible after cognitive behavioural therapy for chronic fatigue syndrome? Psychother. Psychosom. 76, 171–176. doi: 10.1159/000099844
Komaroff, A. L. (1994). “Clinical presentation and evaluation of fatigue and chronic fatigue syndrome,” in Chronic Fatigue Syndrome, ed S. E. Straus (New York; Basel; Hong Kong: Marcel Dekker), 61–84.
Komaroff, A. L., Fagioli, L. R., Doolittle, T. H., Gandek, B., Gleit, M. A., Guerriero, R. T., et al. (1996). Health status in patients with chronic fatigue syndrome and in general population and disease comparison groups. Am. J. Med. 101, 281–290. doi: 10.1016/S0002-9343(96)00174-X
LaManca, J. J., Peckerman, A., Walker, J., Kesil, W., Cook, S., Taylor, A., et al. (1999). Cardiovascular response during head-up tilt in chronic fatigue syndrome. Clin. Physiol. 19, 111–120. doi: 10.1046/j.1365-2281.1999.00154.x
LaManca, J. J., Sisto, S. A., DeLuca, J., Johnson, S., Lange, G., Pareja, J., et al. (1998). Influence of exhaustive treadmill exercise on cognitive functioning in chronic fatigue syndrome. Am. J. Med. 105, 59S–65S. doi: 10.1016/S0002-9343(98)00171-5
Lange, G., DeLuca, J., Maldjian, J. A., Lee, H., Tiersky, L. A., and Natelson, B. H. (1999). Brain MRI abnormalities exist in a subset of patients with chronic fatigue syndrome. J. Neurol. Sci. 171, 3–7. doi: 10.1016/S0022-510X(99)00243-9
Lange, G., Steffener, J., Cook, D. B., Bly, B. M., Christodoulou, C., Liu, W. C., et al. (2005). Objective evidence of cognitive complaints in chronic fatigue syndrome: a BOLD fMRI study of verbal working memory. Neuroimage 26, 513–524. doi: 10.1016/j.neuroimage.2005.02.011
Lawrie, S. M., MacHale, S. M., Cavanagh, J. T., O'Carroll, R. E., and Goodwin, G. M. (2000). The difference in patterns of motor and cognitive function in chronic fatigue syndrome and severe depressive illness. Psychol. Med. 30, 433–442. doi: 10.1017/S0033291799001816
Lerner, A. M., Beqaj, S. H., Fitzgerald, J. T., Gill, K., Gill, C., and Edington, J. (2010). Subset-directed antiviral treatment of 142 herpesvirus patients with chronic fatigue syndrome. Virus Adapt. Treat. 2, 47–57. doi: 10.2147/VAAT.S10695
Light, A. R., Bateman, L., Jo, D., Hughen, R. W., Vanhaitsma, T. A., White, A. T., et al. (2012). Gene expression alterations at baseline and following moderate exercise in patients with chronic fatigue syndrome, and fibromyalgia syndrome. J. Intern. Med. 271, 64–81. doi: 10.1111/j.1365-2796.2011.02405.x
Lo, C. C., Nunes Amaral, L. A., Havlin, S., Ivanov, C., Penzel, T., Peter, J. H., et al. (2002). Dynamics of sleep-wake transitions during sleep. Europhys. Lett. 57, 625–631. doi: 10.1209/epl/i2002-00508-7
Lorusso, L., Mikhaylova, S. V., Capelli, E., Ferrari, D., Ngonga, G. K., and Ricevuti, G. (2009). Immunological aspects of chronic fatigue syndrome. Autoimmun. Rev. 8, 287–291. doi: 10.1016/j.autrev.2008.08.003
Lutgendorf, S., Klimas, N. G., Antoni, M., Brickman, A., and Fletcher, M. A. (1995). Relationships of cognitive difficulties to immune measures, depression and illness burden in chronic fatigue syndrome. J. Chronic Fatigue Syndr. 1, 23–41. doi: 10.1300/J092v01n02_03
MacHale, S. M., Cavanagh, J. T., Bennie, J., Carroll, S., Goodwin, G. M., and Lawrie, S. M. (1998). Diurnal variation of adrenocortical activity in chronic fatigue syndrome. Neuropsychobiology 38, 213–217. doi: 10.1159/000026543
Maes, M., Mihaylova, I., Kubera, M., and Bosmans, E. (2007b). Not in the mind but in the cell: increased production of cyclo-oxygenase-2 and inducible NO synthase in chronic fatigue syndrome. Neuro Endocrinol. Lett. 28, 463–469.
Maes, M., Mihaylova, I., and Leunis, J. C. (2007a). Increased serum IgA and IgM against LPS of enterobacteria in chronic fatigue syndrome (CFS): indication for the involvement of gram-negative enterobacteria in the etiology of CFS and for the presence of an increased gut-intestinal permeability. J. Affect. Disord. 99, 237–240. doi: 10.1016/j.jad.2006.08.021
Maes, M., and Twisk, F. N. M. (2010). Chronic fatigue syndrome: Harvey and Wessely's (bio)psychosocial model versus a bio(psychosocial) model based on inflammatory and oxidative and nitrosative stress pathways. BMC Med. 8:35. doi: 10.1186/1741-7015-8-35
Maes, M., Twisk, F. N. M., and Johnson, C. (2012a). Myalgic encephalomyelitis (ME), chronic fatigue syndrome (CFS), and chronic fatigue (CF) are distinguished accurately: results of supervised learning techniques applied on clinical and inflammatory data. Psychiatry Res. 200, 754–760. doi: 10.1016/j.psychres.2012.03.031
Maes, M., Twisk, F. N. M., Kubera, M., and Ringel, K. (2012b). Evidence for inflammation and activation of cell-mediated immunity in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): increased interleukin-1, tumor necrosis factor-α, PMN-elastase, lysozyme and neopterin. J. Affect. Disord. 136, 933–939. doi: 10.1016/j.jad.2011.09.004
Maes, M., Twisk, F. N. M., Kubera, M., Ringel, K., Leunis, J. C., and Geffard, M. (2012c). Increased IgA responses to the LPS of commensal bacteria is associated with inflammation and activation of cell-mediated immunity in chronic fatigue syndrome. J. Affect. Disord. 136, 909–917. doi: 10.1016/j.jad.2011.09.010
Mathew, S. J., Mao, X., Keegan, K. A., Levine, S. M., Smith, E. L., Heier, L. A., et al. (2009). Ventricular cerebrospinal fluid lactate is increased in chronic fatigue syndrome compared with generalized anxiety disorder: an in vivo 3.0 T (1)H MRS imaging study. NMR Biomed. 22, 251–258. doi: 10.1002/nbm.1315
McHorney, C. A., Ware, J. E. Jr., and Raczek, A. E. (1993). The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med. Care 31, 247–263. doi: 10.1097/00005650-199303000-00006
Meeus, M., Nijs, J., Hermans, L., Goubert, D., and Calders, P. (2013). The role of mitochondrial dysfunctions due to oxidative and nitrosative stress in the chronic pain or chronic fatigue syndromes and fibromyalgia patients: peripheral and central mechanisms as therapeutic targets? Expert Opin. Ther. Targets 17, 1081–1089. doi: 10.1517/14728222.2013.818657
Millard, A. L., Valli, P. V., Stussi, G., Mueller, N. J., Yung, G. P., and Seebach, J. D. (2013). Brief exercise increases peripheral blood NK cell counts without immediate functional changes, but impairs their responses to ex vivo stimulation. Front. Immunol. 4:125. doi: 10.3389/fimmu.2013.00125
Miwa, K., and Fujita, M. (2009). Cardiac function fluctuates during exacerbation and remission in young adults with chronic fatigue syndrome and “small heart”. J. Cardiol. 54, 29–35. doi: 10.1016/j.jjcc.2009.02.008
Montoya, J. G., Kogelnik, A. M., Bhangoo, M., Lunn, M. R., Flamand, L., Merrihew, L. E., et al. (2013). Randomized clinical trial to evaluate the efficacy and safety of valganciclovir in a subset of patients with chronic fatigue syndrome. J. Med. Virol. 85, 2101–2109. doi: 10.1002/jmv.23713
Nacul, L. C., Lacerda, E. M., Pheby, D., Campion, P., Molokhia, M., Fayyaz, S., et al. (2011). Prevalence of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) in three regions of England: a repeated cross-sectional study in primary care. BMC Med. 9:91. doi: 10.1186/1741-7015-9-91
Natelson, B. H., Weaver, S. A., Tseng, C. L., and Ottenweller, J. E. (2005). Spinal fluid abnormalities in patients with chronic fatigue syndrome. Clin. Diagn. Lab. Immunol. 12, 52–55. doi: 10.1128/CDLI.12.1.52-55.2005
Nicolson, G. L., Gan, R., and Haier, J. (2003). Multiple co-infections (Mycoplasma, Chlamydia, human herpes virus-6) in blood of chronic fatigue syndrome patients: association with signs and symptoms. APMIS 111, 557–566. doi: 10.1034/j.1600-0463.2003.1110504.x
Ocon, A. J., Messer, Z., Medow, M., and Stewart, J. (2012). Increasing orthostatic stress impairs neurocognitive functioning in chronic fatigue syndrome with postural tachycardia syndrome. Clin. Sci. 122, 227–238. doi: 10.1042/CS20110241
Patarca, R., Klimas, N. G., Garcia, M. N., Walters, M. J., Dombroski, D., Pons, H., et al. (1995). Dysregulated expression of soluble immune mediator receptors in a subset of patients with chronic fatigue syndrome: cross-sectional categorization of patients by immune status. J. Chronic Fatigue Syndr. 1, 79–94. doi: 10.1300/J092v01n01_06
Patrick Neary, J., Roberts, A. D., Leavins, N., Harrison, M. F., Croll, J. C., and Sexsmith, J. R. (2008). Prefrontal cortex oxygenation during incremental exercise in chronic fatigue syndrome. Clin. Physiol. Funct. Imaging 28, 364–372. doi: 10.1111/j.1475-097X.2008.00822.x
Paul, L., Wood, L., Behan, W. M., and Maclaren, W. M. (1999). Demonstration of delayed recovery from fatiguing exercise in chronic fatigue syndrome. Eur. J. Neurol. 6, 63–69. doi: 10.1046/j.1468-1331.1999.610063.x
Peckerman, A., LaManca, J. J., Dahl, K. A., Chemitiganti, R., Qureishi, B., and Natelson, B. H. (2003). Abnormal impedance cardiography predicts symptom severity in chronic fatigue syndrome. Am. J. Med. Sci. 326, 55–60. doi: 10.1097/00000441-200308000-00001
Pietrangelo, T., Mancinelli, R., Toniolo, L., Toniolo, L., Vecchiet, J., Fanò, G., et al. (2009). Transcription profile analysis of vastus lateralis muscle from patients with chronic fatigue syndrome. Int. J. Immunopathol. Pharmacol. 22, 795–807.
Porter, N., Lerch, A., Jason, L. A., Sorenson, M., Fletcher, M. A., and Herrington, J. (2010). A comparison of immune functionality in viral versus non-viral CFS subtypes. J. Behav. Neurosci. Res. 8, 1–8.
Puri, B. K., Jakeman, P. M., Agour, M., Gunatilake, K. D., Fernando, K. A., Gurusinghe, A. I., et al. (2012). Regional grey and white matter volumetric changes in myalgic encephalomyelitis (chronic fatigue syndrome): a voxel-based morphometry 3 T MRI study. Br. J. Radiol. 85, e270–e273. doi: 10.1259/bjr/93889091
Ray, C., Jefferies, S., and Weir, W. R. (1997). Coping and other predictors of outcome in chronic fatigue syndrome: a 1-year follow-up. J. Psychosom. Res. 43, 405–415. doi: 10.1016/S0022-3999(97)00111-6
Reeves, W. C., Wagner, D., Nisenbaum, R., Jones, J. F., Gurbaxani, B., Solomon, L., et al. (2005). Chronic fatigue syndrome - a clinically empirical approach to its definition and study. BMC Med. 3:19. doi: 10.1186/1741-7015-3-19
Reyes, M., Dobbins, J. G., Nisenbaum, R., Subedar, N., Randall, B., and Reeves, W. C. (1998). Chronic fatigue syndrome progression and self-defined recovery: evidence from the CDC surveillance system. J. Chronic Fatigue Syndr. 5, 17–27. doi: 10.1300/J092v05n01_03
Roelant, C., and de Meirleir, K. (2012). Self-test monitoring of the Th1/Th2 balance in health and disease with special emphasis on chronic fatigue syndrome/myalgic encephalomyelitis. JMLD 3, 1–6. doi: 10.5897/JMLD11.023
Sakharov, D. A., Maltseva, D. V., Riabenko, E. A., Shkurnikov, M. U., Northoff, H., Tonevitsky, A. G., et al. (2012). Passing the anaerobic threshold is associated with substantial changes in the gene expression profile in white blood cells. Eur. J. Appl. Physiol. 112, 963–972. doi: 10.1007/s00421-011-2048-3
Schutzer, S. E., Angel, T. E., Liu, T., Schepmoes, A. A., Clauss, T. R., Adkins, J. A., et al. (2011). Distinct cerebrospinal fluid proteomes differentiate post-treatment lyme disease from chronic fatigue syndrome. PLoS ONE 6:e17287. doi: 10.1371/journal.pone.0017287
Scott, L. V., Teh, J., Reznek, R., Martin, A., Sohaib, A., and Dinan, T. G. (1999). Small adrenal glands in chronic fatigue syndrome: a preliminary computer tomography study. Psychoneuroendocrinology 24, 759–768. doi: 10.1016/S0306-4530(99)00028-1
Sheedy, J. R., Wettenhall, R. E., Scanlon, D., Gooley, P. R., Lewis, D. P., McGregor, N., et al. (2009). Increased d-lactic acid intestinal bacteria in patients with chronic fatigue syndrome. In Vivo 23, 621–628.
Shungu, D. C., Weiduschat, N., Murrough, J. W., Mao, X., Pillemer, S., Dyke, J. P., et al. (2012). Increased ventricular lactate in chronic fatigue syndrome. III. Relationships to cortical glutathione and clinical symptoms implicate oxidative stress in disorder pathophysiology. NMR Biomed. 25, 1073–1087. doi: 10.1002/nbm.2772
Siegel, S. D., Antoni, M. H., Fletcher, M. A., Maher, K., Segota, M. C., and Klimas, N. (2006). Impaired natural immunity, cognitive dysfunction, and physical symptoms in patients with chronic fatigue syndrome: preliminary evidence for a subgroup. J. Psychosom. Res. 60, 559–566. doi: 10.1016/j.jpsychores.2006.03.001
Siemionow, V., Fang, Y., Calabrese, L., Sahgal, V., and Yue, G. H. (2004). Altered central nervous system signal during motor performance in chronic fatigue syndrome. Clin. Neurophysiol. 115, 2372–2381. doi: 10.1016/j.clinph.2004.05.012
Smylie, A. L., Broderick, G., Fernandes, H., Razdan, S., Barnes, Z., Collado, F., et al. (2013). A comparison of sex-specific immune signatures in Gulf War illness and chronic fatigue syndrome. BMC Immunol. 14:29. doi: 10.1186/1471-2172-14-29
Snell, C. R., Stevens, S. R., Davenport, T. E., and VanNess, J. M. (2013). Discriminative validity of metabolic and workload measurements to identify individuals with chronic fatigue syndrome. Phys. Ther. 93, 1484–1492. doi: 10.2522/ptj.20110368
Stark, T., Walker, B., Phillips, J. K., Fejer, R., and Beck, R. (2011). Hand-held dynamometry correlation with the gold standard isokinetic dynamometry: a systematic review. PM R 3, 472–479. doi: 10.1016/j.pmrj.2010.10.025
Steensberg, A., Toft, A. D., Bruunsgaard, H., Sandmand, M., Halkjaer-Kristensen, J., and Pedersen, B. K. (2001). Strenuous exercise decreases the percentage of type 1 T cells in the circulation. J. Appl. Physiol. 91, 1708–1712.
Stewart, J. M., Gewitz, M. H., Weldon, A., Arlievsky, N., Li, K., and Munoz, J. (1999). Orthostatic intolerance in adolescent chronic fatigue syndrome. Pediatrics 103, 116–121. doi: 10.1542/peds.103.1.116
Suárez, A., Guillamo, E., Roig, T., Blázquez, A., Alegre, J., Bermúdez, J., et al. (2010). Nitric oxide metabolite production during exercise in chronic fatigue syndrome: a case-control study. J. Womens. Health (Larchmt). 19, 1073–1077. doi: 10.1089/jwh.2008.1255
Tak, L. M., Cleare, A. J., Ormel, J., Manoharan, A., Kok, I. C., Wessely, S., et al. (2011). Meta-analysis and meta-regression of hypothalamic-pituitary-adrenal axis activity in functional somatic disorders. Biol. Psychol. 87, 183–194. doi: 10.1016/j.biopsycho.2011.02.002
Task Force for the Diagnosis and Management of Syncope, European Society of Cardiology (ESC), European Heart Rhythm Association (EHRA), Heart Failure Association (HFA), and Heart Rhythm Society (HRS). (2009). Guidelines for the diagnosis and management of syncope (version 2009). Eur. Heart J. 30, 2631–2671. doi: 10.1093/eurheartj/ehp298
Thambirajah, A. A., Sleigh, K., Stiver, H. G., and Chow, A. W. (2008). Differential heat shock protein responses to strenuous standardized exercise in chronic fatigue syndrome patients and matched healthy controls. Clin. Invest. Med. 31, E319–E327.
Tiersky, L. A., Johnson, S. K., Lange, G., Natelson, B. H., and DeLuca, J. (1997). Neuropsychology of chronic fatigue syndrome: a critical review. J. Clin. Exp. Neuropsychol. 19, 560–586. doi: 10.1080/01688639708403744
Torres-Harding, S., Sorenson, M., Jason, L., Maher, K., Fletcher, M. A., Reynolds, N., et al. (2008). The associations between basal salivary cortisol and illness symptomatology in chronic fatigue syndrome. J. Appl. Biobehav. Res. 13, 157–180. doi: 10.1111/j.1751-9861.2008.00033.x
Twisk, F. N. M., and Arnoldus, R. J. W. (2012). Graded exercise therapy (GET)/cognitive behavioural therapy (CBT) is often counterproductive in myalgic encephalomyelitis (ME) and chronic fatigue syndrome (CFS). Eur. J. Clin. Invest. 42, 1255–1256. doi: 10.1111/j.13652362.2012.02718.x
Twisk, F. N. M., and Arnoldus, R. J. W. (2013). Comment and reply on: ME is a distinct diagnostic entity, not part of a chronic fatigue spectrum. Expert Opin. Med. Diagn. 7, 413–415. doi: 10.1517/17530059.2013.795147
Van der Werf, S. P., de Vree, B., Alberts, M., van der Meer, J. W. M., and Bleijenberg, G. (2002). Netherlands Fatigue Research Group Nijmegen. Natural course and predicting self-reported improvement in patients with chronic fatigue syndrome with a relatively short illness duration. J. Psychosom. Res. 53, 749–753. doi: 10.1016/S0022-3999(02)00324-0
VanNess, J. M., Snell, C. R., Stevens, S. R., Bateman, L., and Keller, B. A. (2006). Using serial cardiopulmonary exercise tests to support a diagnosis of chronic fatigue syndrome. Med. Sci. Sports Exerc. 38, S85. doi: 10.1249/00005768-200605001-00386
VanNess, J. M., Snell, C. R., Stevens, S. R., and Stiles, T. L. (2007). Metabolic and neurocognitive responses to an exercise challenge in chronic fatigue syndrome (CFS). Med. Sci. Sports Exerc. 39, S445. doi: 10.1249/01.mss.0000274760.28522.df
Vercoulen, J. H. M. M., Swanink, C. M. A., Fennis, J. F. M., Galama, J. M. D., van der Meer, J. W. M., and Bleijenberg, G. (1994). Dimensional assessment of chronic fatigue syndrome. J. Psychosom. Res. 38, 383–392. doi: 10.1016/0022-3999(94)90099-X
Vermeulen, R. C., and Vermeulen van Eck, I. W. (2014). Decreased oxygen extraction during cardiopulmonary exercise test in patients with chronic fatigue syndrome. J. Transl. Med. 12, 20. doi: 10.1186/1479-5876-12-20
Vermeulen, R. C. W., Kurk, R. M., Visser, F. C., Sluiter, W., and Scholte, H. R. (2010). Patients with chronic fatigue syndrome performed worse than controls in a controlled repeated exercise study despite a normal oxidative phosphorylation capacity. J. Transl. Med. 8, 93. doi: 10.1186/1479-5876-8-93
Wang, C. Y., Olson, S. L., and Protas, E. J. (2002). Test-retest strength reliability: hand-held dynamometry in community-dwelling elderly fallers. Arch. Phys. Med. Rehabil. 83, 811–815. doi: 10.1053/apmr.2002.32743
Watson, W. S., McCreath, G. T., Chaudhuri, A., and Behan, P. O. (1997). Possible cell membrane transport defect in chronic fatigue syndrome? J. Chronic Fatigue Syndr. 3, 1–13. doi: 10.1300/J092v03n03_01
Watt, T., Oberfoell, S., Balise, R., Lunn, M. R., Kar, A. K., Merrihew, L., et al. (2012). Response to valganciclovir in chronic fatigue syndrome patients with human herpesvirus 6 and Epstein-Barr virus IgG antibody titers. J. Med. Virol. 84, 1967–1974. doi: 10.1002/jmv.23411
Weinstein, A. A., Drinkard, B. M., Diao, G., Furst, G., Dale, J. K., Straus, S. E., et al. (2009). Exploratory analysis of the relationships between aerobic capacity and self-reported fatigue in patients with rheumatoid arthritis, polymyositis, and chronic fatigue syndrome. PM R 1, 620–628. doi: 10.1016/j.pmrj.2009.04.007
Whistler, T., Jones, J. F., Unger, E. R., and Vernon, S. D. (2005). Exercise responsive genes measured in peripheral blood of women with chronic fatigue syndrome and matched control subjects. BMC Physiol. 5:5. doi: 10.1186/1472-6793-5-5
Whistler, T., Unger, E. R., Nisenbaum, R., and Vernon, S. D. (2003). Integration of gene expression, clinical, and epidemiologic data to characterize chronic fatigue syndrome. J. Transl. Med. 1, 10. doi: 10.1186/1479-5876-1-10
White, A. T., Light, A. R., Hughen, R. W., Bateman, L., Martins, T. B., Hill, H. R., et al. (2010). Severity of symptom flare after moderate exercise is linked to cytokine activity in chronic fatigue syndrome. Psychophysiology 47, 615–624. doi: 10.1111/j.1469-8986.2010.00978.x
White, A. T., Light, A. R., Hughen, R. W., Vanhaitsma, T. A., and Light, K. C. (2012). Differences in metabolite-detecting, adrenergic, and immune gene expression after moderate exercise in patients with chronic fatigue syndrome, patients with multiple sclerosis, and healthy controls. Psychosom. Med. 74, 46–54. doi: 10.1097/PSY.0b013e31824152ed
White, P. D., Goldsmith, K. A., Johnson, A. L., Potts, L., Walwyn, R., DeCesare, J. C., et al. (2011). Comparison of adaptive pacing therapy, cognitive behaviour therapy, graded exercise therapy, and specialist medical care for chronic fatigue syndrome (PACE): a randomised trial. Lancet 377, 823–836. doi: 10.1016/S0140-6736(11)60096-2
Wilson, A., Hickie, I., Hadzi-Pavlovic, D., Wakefield, D., Parker, G., Straus, S. E., et al. (2001). What is chronic fatigue syndrome? Heterogeneity within an international multicentre study. Aust. N.Z. J. Psychiatry 35, 520–527. doi: 10.1046/j.1440-1614.2001.00888.x
Wyller, V. B., Due, R., Saul, J. P., Amlie, J. P., and Thaulow, E. (2007). Usefulness of an abnormal cardiovascular response during low-grade head-up tilt-test for discriminating adolescents with chronic fatigue from healthy controls. Am. J. Cardiol. 99, 997–1001. doi: 10.1016/j.amjcard.2006.10.067
Yoshiuchi, K., Farkas, J., and Natelson, B. H. (2006). Patients with chronic fatigue syndrome have reduced absolute cortical blood flow. Clin. Physiol. Funct. Imaging 26, 83–86. doi: 10.1111/j.1475-097X.2006.00649.x
Zhang, C., Baumer, A., Mackay, I. R., Linnane, A. W., and Nagley, P. (1995). Unusual pattern of mitochondrial DNA deletions in skeletal muscle of an adult human with chronic fatigue syndrome. Hum. Mol. Genet. 4, 751–754. doi: 10.1093/hmg/4.4.751
Zhang, L., Gough, J., Christmas, D., Mattey, D. L., Richards, S. C., Main, J., et al. (2010). Microbial infections in eight genomic subtypes of chronic fatigue syndrome/myalgic encephalomyelitis. J. Clin. Pathol. 63, 156–164. doi: 10.1136/jcp.2009.072561
Keywords: Myalgic Encephalomyelitis, Chronic Fatigue Syndrome, assessment, diagnosis, immune system, post-exertional malaise, subgroups
Citation: Twisk FNM (2014) The status of and future research into Myalgic Encephalomyelitis and Chronic Fatigue Syndrome: the need of accurate diagnosis, objective assessment, and acknowledging biological and clinical subgroups. Front. Physiol. 5:109. doi: 10.3389/fphys.2014.00109
Received: 06 February 2014; Accepted: 04 March 2014;
Published online: 27 March 2014.
Edited by:Niels H. Secher, University of Copenhagen, Denmark
Reviewed by:Niels H. Secher, University of Copenhagen, Denmark
Niels Vidiendal Olsen, Rigshospitalet, Denmark
Copyright © 2014 Twisk. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Frank N. M. Twisk, ME-de-Patiënten Foundation, Zonnedauw 15, 1906 HB Limmen, Netherlands e-mail: email@example.com